How does anemia affect hemoglobin A1c (HbA1c) results?

How Anemia Affects HbA1c Results

Anemia affects HbA1c in opposite directions depending on the type: hemolytic anemia falsely lowers HbA1c values, while iron-deficiency anemia falsely increases HbA1c levels—both independent of actual glycemic control. 1

The Core Problem: Red Blood Cell Turnover

HbA1c reflects average glucose exposure over the lifespan of red blood cells (approximately 120 days). When anemia disrupts normal RBC turnover, HbA1c becomes unreliable as a glycemic marker regardless of which assay method you use 1.

Hemolytic Anemia: Falsely Low HbA1c

Any condition that shortens RBC survival or decreases mean RBC age will falsely lower HbA1c compared to true mean glycemia 1. This includes:

• Hemolytic anemia
• Recovery from acute blood loss
• Sickle cell disease
• Pregnancy (due to increased RBC turnover)

The mechanism is straightforward: younger red blood cells have had less time to accumulate glycated hemoglobin, so the measured HbA1c underestimates actual glucose exposure 1. Normal RBC half-life ranges from 48-68 days (mean 58 days), and this variability alone explains some of the interindividual differences between measured glucose and HbA1c 1.

Iron-Deficiency Anemia: Falsely Elevated HbA1c

Iron-deficiency anemia increases HbA1c test results independent of glycemic status 1. Multiple large-scale studies confirm this:

• A retrospective analysis of over 12,000 IDA patients showed median HbA1c of 5.7% in females with IDA versus 5.4% without IDA (p<0.001), and 6.0% versus 5.6% in males (p<0.001) 2
• Studies consistently demonstrate a positive correlation between HbA1c and serum ferritin, hemoglobin, MCV, MCH, and MCHC 3, 4
• In euglycemic diabetic patients with controlled blood glucose, anemic patients had significantly higher median HbA1c than non-anemic patients despite identical glucose control 3

The proposed mechanisms include altered erythrocyte turnover, structural hemoglobin modifications, and oxidative stress-induced glycation 5.

Critical Clinical Implications

When you encounter discordant HbA1c and glucose values, immediately check for anemia and iron status before making therapeutic decisions 1, 2. This is particularly crucial in:

• Premenopausal women (high IDA prevalence)
• Pregnant women (altered RBC turnover plus potential IDA)
• Patients with chronic diseases affecting RBC production
• Anyone with hemoglobinopathies

What to Do Instead

The 2023 ADA/AACC guidelines explicitly state that glucose testing—not HbA1c—must be used for screening, diagnosis, and management when disorders affecting RBC turnover are present 1.

Alternative markers include:

• Fructosamine or glycated albumin: These reflect 2-3 weeks of glycemic control rather than 2-3 months, making them independent of RBC lifespan 1
• Continuous glucose monitoring or frequent glucose testing: Direct measurement bypasses the HbA1c interference entirely
• Corrected HbA1c calculations: Though less validated 6

The Iron Replacement Caveat

Iron replacement therapy normalizes HbA1c levels in IDA patients, confirming that the elevation was spurious 5. This means:

• If you diagnose diabetes based on elevated HbA1c in an IDA patient, you may be overdiagnosing diabetes
• After treating IDA, recheck HbA1c to determine true glycemic status
• Don't intensify diabetes therapy based solely on HbA1c in untreated IDA

Common Pitfalls to Avoid

1. Don't assume HbA1c is universally reliable: Always consider RBC disorders when values don't match clinical picture
2. Don't ignore mild anemia: Even moderate anemia significantly affects HbA1c interpretation 3
3. Don't use HbA1c in homozygous hemoglobinopathies (HbSS, HbEE): It cannot be measured accurately and should not be reported 1
4. Don't forget pregnancy: RBC turnover changes lower HbA1c in normal pregnancy, independent of any anemia 1

The Bottom Line Algorithm

When evaluating HbA1c results:

1. Check CBC and iron studies if HbA1c doesn't match glucose values or clinical picture
2. If hemolytic anemia present: HbA1c underestimates glycemia → use glucose monitoring or alternative markers
3. If iron-deficiency anemia present: HbA1c overestimates glycemia → treat IDA first, then reassess, or use alternative markers
4. If any RBC turnover disorder: Don't use HbA1c for diagnosis or management decisions 1

The evidence is clear and consistent across guidelines: HbA1c reliability depends entirely on normal RBC lifespan, and anemia disrupts this fundamental assumption in predictable, clinically significant ways.